Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Consumer experts: German petrol hikes rule won't bring down prices - 2Israeli media reports Iran attacking greater Tel Aviv region
- 3'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- 4Far-right German youth group delegates seek deportations, remigration
- 5UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
- Grasping the Commencement of Criminal Cases: An Extensive Outline
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- New science points to 4 distinct types of autism
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- Before Cheap Cars Were Common, This Fiat Changed Everyday Life for Millions
- Culinary Joys: Investigating Connoisseur Cooking at Home
- Outside Lovers' Decision: Favored Climbing Rucksacks
